Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.64 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | TCF4 | P15884 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19175769 | 0.86 | DGAT1 (0.77) | DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL19175760 | 0.83 | DGAT1 (0.52) | DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL14128465 | 0.79 | DGAT1 (0.80) | DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL14128411 | 0.79 | DGAT1 (0.80) | DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL14128551 | 0.78 | CYP11B1 (0.65) | DGAT1CYP11B1TCF4CTNNB1 | |
| SCHEMBL31195875 | 0.78 | MGLL (0.48) | DGAT1KCNH2ADORA2A | |
| SCHEMBL10146483 | 0.78 | DGAT1 (0.81) | DGAT1KCNH2ADORA2A | |
| SCHEMBL14235529 | 0.77 | DGAT1 (0.66) | DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL14127762 | 0.77 | DGAT1 (0.84) | DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL14128558 | 0.77 | DGAT1 (0.84) | DGAT1KCNH2ADORA2ASOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210741-A1 | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof | SOUTHERN RESEARCH INSTITUTE | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210741-A1 | Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof | WNT1, WNT3, CTNNB1 | DGAT1 2252/4885KCNH2 4391/4885ADORA2A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.